Syndax Pharmaceuticals (SNDX) Key Ratios

$20.73

up-down-arrow $0.05 (0.22%)

As on 04-Sep-2026 13:37EDT

Market cap

info icon

$1,745 Mln

Revenue (TTM)

info icon

$252 Mln

P/E Ratio

info icon

--

P/B Ratio

info icon

119.3

Div. Yield

info icon

0 %

Key Ratios and Highlights

Growth Score (%) Quarterly Annual (TTM)
Particulars QoQ YoY 1-Year 3-Years 5-Years
Revenue 12.22 91.76 222.34 10.84 178.03
EBIT -- -- 70.78 11.28 -2.18
Net Profit -15.68 31.29 34.10 -14.59 -183.79
EPS -12.60 33.34 35.13 -1.34 -8.02
Book Value -- -- -77.78 -53.45 -32.88
Key Ratios (%) Average Annual (TTM)
Particulars3-Years5-YearsTTMDec-25Dec-24
EBIT-Margin info -735.65-393.10-39.11-146.00-1,325.29
Net Margin info --17.76-87.60----
Return on equity info -92.83-60.75-553.79-161.82-75.69
Return on Capital info -49.70-34.80---54.63-53.59
Return on Assets info -43.63-30.92-29.19-45.50-47.66
Debt to Equity (x) info ----38.955.361.20
ROCE

--

--

Earning before interest and taxes / (Average net worth + Average total Debt) * 100

Company Name
TTM
Dec-25
Dec-24
Dec-23
Dec-22
Syndax Pharmaceuticals (SNDX)
--
-54.63
-53.59
-40.87
-32.02
Peer Median
--
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
ROE

-553.79

Lower than Peers by 513.39

Profit after tax / Average Net worth * 100

Company Name
TTM
Dec-25
Dec-24
Dec-23
Dec-22
Syndax Pharmaceuticals (SNDX)
-553.79
-161.82
-75.69
-40.98
-32.83
Peer Median
-40.40
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
ROA

-29.19

Higher than Peers by 1.79

Profit after tax / Average Total assets * 100

Company Name
TTM
Dec-25
Dec-24
Dec-23
Dec-22
Syndax Pharmaceuticals (SNDX)
-29.19
-45.50
-47.66
-37.72
-30.36
Peer Median
-30.98
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
EBIT Margin

-39.11

Higher than Peers by 44.50

Operating profit (EBIT) / Net Sales * 100

Company Name
TTM
Dec-25
Dec-24
Dec-23
Dec-22
Syndax Pharmaceuticals (SNDX)
-39.11
-146.00
-1,325.29
--
-119.89
Peer Median
-83.62
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Net Margin

-87.60

Higher than Peers by 5.07

Net profit / Total Income (Net sales plus other income) * 100

Company Name
TTM
Dec-25
Dec-24
Dec-23
Dec-22
Syndax Pharmaceuticals (SNDX)
-87.60
-165.60
-1,346.11
--
-113.57
Peer Median
-92.67
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Cash Profit Margin

-0.01

Lower than Peers by 0.01

(Net profit + Depreciation) / Gross Sales * 100

Company Name
TTM
Dec-25
Dec-24
Dec-23
Dec-22
Syndax Pharmaceuticals (SNDX)
-0.01
--
--
--
--
Peer Median
0.00
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Revenue Growth

222.34

Higher than Peers by 168.38

Year on year growth in net sales

Company Name
TTM
Dec-25
Dec-24
Dec-23
Dec-22
Syndax Pharmaceuticals (SNDX)
222.34
6.28
--
-1.00
-0.09
Peer Median
53.95
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
EBIT Growth

70.78

Higher than Peers by 71.58

Year on year growth in operating profit (EBIT)

Company Name
TTM
Dec-25
Dec-24
Dec-23
Dec-22
Syndax Pharmaceuticals (SNDX)
70.78
19.82
-50.05
-37.82
-678.78
Peer Median
-0.80
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Net Profit Growth

34.10

Higher than Peers by 41.40

Year on year growth in profit after tax

Company Name
TTM
Dec-25
Dec-24
Dec-23
Dec-22
Syndax Pharmaceuticals (SNDX)
34.10
10.46
-52.25
-45.64
-676.70
Peer Median
-7.30
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
EPS Growth

35.13

Higher than Peers by 20.48

Year on year growth in earnings per share

Company Name
TTM
Dec-25
Dec-24
Dec-23
Dec-22
Syndax Pharmaceuticals (SNDX)
35.13
0.11
-0.29
-0.27
-5.85
Peer Median
14.65
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Book Value Growth

-90.69

Lower than Peers by 80.52

Year on year growth in book value per share

Company Name
TTM
Dec-25
Dec-24
Dec-23
Dec-22
Syndax Pharmaceuticals (SNDX)
-90.69
--
--
--
--
Peer Median
-10.18
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Debt to Equity

38.95

--

Total debt / Net worth

Company Name
TTM
Dec-25
Dec-24
Dec-23
Dec-22
Syndax Pharmaceuticals (SNDX)
38.95
5.36
1.20
0.00
0.00
Peer Median
--
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Short term debt to equity ratio

0.03

--

(Short term borrowings / Net worth)

Company Name
TTM
Dec-25
Dec-24
Dec-23
Dec-22
Syndax Pharmaceuticals (SNDX)
0.03
0.01
0.04
0.00
0.00
Peer Median
--
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Current Ratio

6.77

Higher than Peers by 0.96

Current Assets / Current Liabilities and Provisions

Company Name
TTM
Dec-25
Dec-24
Dec-23
Dec-22
Syndax Pharmaceuticals (SNDX)
6.77
4.40
5.82
10.00
16.85
Peer Median
5.81
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Quick Ratio

6.44

Higher than Peers by 0.74

(Current Assets - Inventory) / Current Liabilities and Provisions

Company Name
TTM
Dec-25
Dec-24
Dec-23
Dec-22
Syndax Pharmaceuticals (SNDX)
6.44
4.12
5.82
9.96
17.00
Peer Median
5.70
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Interest Coverage

-1.58

Higher than Peers by 0.51

Earning before interest and taxes (EBIT) / Interest Expenses

Company Name
TTM
Dec-25
Dec-24
Dec-23
Dec-22
Syndax Pharmaceuticals (SNDX)
-1.58
-7.45
-63.67
-1,005.54
-48.38
Peer Median
-2.09
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.

Operating Efficiency

View Detailed Peer Comparison

Debtors to sales

27.84

Higher than Peers by 8.70

Debtors outstanding / Net Sales * 100

Company Name
TTM
Dec-25
Dec-24
Dec-23
Dec-22
Syndax Pharmaceuticals (SNDX)
27.84
40.78
58.58
--
3.21
Peer Median
19.14
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Asset Turnover

0.33

Higher than Peers by 0.27

Sales / Average Total Assets

Company Name
TTM
Dec-25
Dec-24
Dec-23
Dec-22
Syndax Pharmaceuticals (SNDX)
0.33
0.27
0.04
--
0.27
Peer Median
0.06
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Receivable days

--

--

Average Debtors / Sales * 365

Company Name
TTM
Dec-25
Dec-24
Dec-23
Dec-22
Syndax Pharmaceuticals (SNDX)
--
89.18
116.44
--
6.47
Peer Median
--
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Inventory Days

--

--

Average Inventory / Sales * 365

Company Name
TTM
Dec-25
Dec-24
Dec-23
Dec-22
Syndax Pharmaceuticals (SNDX)
--
867.80
523.78
-34,211.75
1,367.68
Peer Median
--
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Payable days

--

--

Average Creditors / Cost of goods sold * 365

Company Name
TTM
Dec-25
Dec-24
Dec-23
Dec-22
Syndax Pharmaceuticals (SNDX)
--
739.04
4,772.79
217,795.53
4,030.22
Peer Median
--
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Cash Conversion Cycle

--

--

Receivable Days + Inventory Days - Payable Days

Company Name
TTM
Dec-25
Dec-24
Dec-23
Dec-22
Syndax Pharmaceuticals (SNDX)
--
217.93
-4,132.58
--
-2,656.07
Peer Median
--
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Price / Earnings

--

--

Current share price divided by earning per share in the last twelve months

Company Name
TTM
Dec-25
Dec-24
Dec-23
Dec-22
Syndax Pharmaceuticals (SNDX)
--
-6.38
-3.56
-7.49
-11.19
Peer Median
--
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Price / Book Value

119.29

Higher than Peers by 114.11

Current share price divided by book value per share in the latest financial year

Company Name
TTM
Dec-25
Dec-24
Dec-23
Dec-22
Syndax Pharmaceuticals (SNDX)
119.29
28.16
3.94
2.83
3.44
Peer Median
5.18
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Dividend Yield

--

--

Dividend per share in the past twelve months divided by current share price

Company Name
TTM
Dec-25
Dec-24
Dec-23
Dec-22
Syndax Pharmaceuticals (SNDX)
--
--
--
--
--
Peer Median
--
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
EV/EBITDA

-105.26

--

Enterprise Value (Current Market Capitalisation + Total Debt - Cash & Equivalents) / Earnings before interest, taxes, depreciation and taxes (EBITDA)

Company Name
TTM
Dec-25
Dec-24
Dec-23
Dec-22
Syndax Pharmaceuticals (SNDX)
-105.26
-6.97
-2.86
-4.74
-7.41
Peer Median
--
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Market Cap

1,745

Higher than Peers by 1,599

Current Share price multiplied by latest total number of shares outstanding

Company Name
TTM
Dec-25
Dec-24
Dec-23
Dec-22
Syndax Pharmaceuticals (SNDX)
1,745
--
--
--
--
Peer Median
146
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
loading...
loading...